Current stock page

Catalysts

LLY Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareDrug Manufacturers - GeneralScore data as of Oct 21, 2026

LLYEli Lilly and Company

Healthcare / Drug Manufacturers - General

Relative Leader / Watch

Strong Relative Position

NeutralEdge 8/10
$1,270.75−$12.91 (−1.01%)

Latest quote

  • Momentum
    95
  • Value
    26
  • Quality
    76
  • Risk resilience
    50
  • Sentiment
    74
algovestiq.comScore data as of Oct 21, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Oct 29, 2026

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 62/100

Momentum 95/100 and sentiment 74/100 before the next covered event.

Recent coverage
5 articles

Updated Oct 21, 2026 · Sentiment 41.89%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 95/100AIQ Edge 8/10 Strong Relative Position
Beat rate
100%
3 of 3 reported periods
Average surprise
+20.9%
Across covered historical reports
Latest result
+30.9%
Aug 5, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Oct 29, 2026—$9.85——$22.16B—
Aug 5, 2026—$6.40$8.38+30.9%$20.82B$22.97B
Apr 30, 2026—$6.97$8.55+22.7%$17.82B$19.8B
Feb 4, 2026—$6.91$7.54+9.1%$17.94B$19.29B

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
26
Buy
3
Hold
2
Sell
12-month analyst target
$1,328.15
+4.52% versus current price
Based on 15 analyst observations. Targets are estimates, not predictions.
Low target
$940.00
-26.03% vs latest price
Average target
$1,328.15
+4.52% vs latest price
High target
$1,500.00
+18.04% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateOct 29, 2026

Next known earnings or reporting date.

EPS estimate$5.65

Current analyst expectation for the upcoming report.

Revenue estimate$22.47B

Current analyst expectation for the upcoming report.

Sentiment score74

News pressure around the setup.

Momentum score95

Where event reaction would show up first.

AIQ score62/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
15
Average target
$1,328.15
Target upside
4.52%
Target range
$940.00 - $1,500.00
90-day revisions
6

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
4
Neutral
1
Negative
0
gurufocus.com · Oct 20, 2026

Eli Lilly (LLY) Shares Hit Record High of $1,311.21 on October 20, 2026

On October 20, 2026, Eli Lilly and Co (NYSE: LLY) shares surged to a new record intraday high of $1,311.21, surpassing its previous peak of $1,292.65 set in Aug

gurufocus.com · Oct 20, 2026

Eli Lilly (LLY) Stock Hits New High at $1311.21 Ahead of Q3 Earnings

On October 20, 2026, Eli Lilly and Co (NYSE: LLY) shares surged to a fresh all-time high of $1311.21 during morning trading, surpassing the previous record of $

manilatimes.net · Oct 20, 2026

Lilly Endowment Awards $10 Million Capacity-Building Grant to Homes For Our Troops to Advance Mission of Building Homes and Rebuilding Lives

Lilly Endowment Awards $10 Million Capacity-Building Grant to Homes For Our Troops to Advance Mission of Building Homes and Rebuilding Lives

insidermonkey.com · Oct 20, 2026

Bristol Myers vs. Eli Lilly: Is BMY’s Deep Valuation Discount Hiding an Opportunity?

Bristol-Myers Squibb Company (NYSE:BMY) and Eli Lilly and Company (NYSE:LLY) are almost opposites in the pharmaceutical market.

gurufocus.com · Oct 19, 2026

Eli Lilly (LLY) Pursues Pediatric Approval for Omvoh After Positive Ulcerative Colitis Trial

On October 19, 2026, Eli Lilly and Co (NYSE: LLY) announced plans to seek regulatory approval for an expanded indication of its bowel disease treatment, Omvoh,

Open full news and sentiment

LLY Catalysts FAQ

What are the next catalysts for LLY stock?

LLY's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move LLY stock?

Upcoming events that could move LLY include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could LLY's next earnings report affect the stock?

LLY's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive LLY stock higher?

LLY could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt LLY stock?

LLY could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.

How could Mounjaro and Zepbound growth affect LLY stock?

Mounjaro and Zepbound can affect LLY through revenue growth, margins, capacity, competitive share, and investor expectations. Use this catalyst page to connect upcoming obesity-drug updates with earnings, analyst targets, and AIQ momentum.